Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Haloperidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 0.92 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.92 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.92 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.92 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.92 |
| ▸ | HTR1A | P08908 | 3/20 | 0.92 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.92 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.92 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.92 |
| ▸ | HRH1 | P35367 | 3/20 | 0.92 |
| ▸ | HTR2C | P28335 | 2/20 | 0.92 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.92 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.92 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.92 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.92 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.92 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20254453 | 0.96 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL8264 | 0.96 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL5070670 | 0.96 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL317367 | 0.95 | DRD2 (0.98) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL15545886 | 0.95 | DRD2 (0.98) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL28699132 | 0.94 | DRD2 (0.96) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL8741248 | 0.93 | DRD2 (0.94) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| SCHEMBL11752117 | 0.92 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL42239 | 0.92 | DRD2 (0.84) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL20644145 | 0.92 | DRD2 (0.92) | DRD2ADRA1AHTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116419749-A | Pharmaceutical formulation for pressurized metered-dose inhalers | 奇斯药制品公司 | 2023-07-11 | — | — | CN | claimed |
| CN-118304422-A | Pharmaceutical composition for treating eye diseases or disorders | 爱瑞制药公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118286445-A | Pharmaceutical composition for treating eye diseases or disorders | 爱瑞制药公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-110290807-B | Methods of determining CAR-T cell dosing | 朱诺治疗学股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-113660952-B | Bispecific antibodies | 小野药品工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-115175667-B | Lipid vesicle compositions with permeation enhancers | 迪迪艾斯研究公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118139614-A | Sterile liposome-containing compositions and articles | 脂肪球有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-111527065-B | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | 科廷大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-117979961-A | Stabilized compositions | 鲁米兰特私人有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-110678543-B | In vitro culture system and method of use thereof | 耶达研究及发展有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116234548-A | Compounds comprising tricyclic parent nucleus as PD-1/PD-L1 blockers | 再生治疗有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116194438-A | Advantageous treatment of Ikaros or Aiolos mediated disorders | C4医药公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-107085113-B | Use of gelsolin for diagnosis and treatment of inflammatory diseases | 布赖汉姆妇女医院有限公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-110770255-A | Multispecific polypeptide constructs with restricted CD3 binding and methods of use thereof | 印希彼有限公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-110545850-A | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB | 2019-12-06 | — | — | CN | disclosed |
| US-10183001-B1 | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features | PISGAH LABORATORIES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-9312497-B2 | Heterocyclic compound, organic light-emitting diode including the heterocyclic compound, and flat display device including the organic light-emitting diode | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-04-12 | — | — | US | disclosed |
| EP-0260070-B1 | THE ACETIC ACID ESTER OF HALOPERIDOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. LUNDBECK A/S (DK) | 1993-08-11 | — | — | EP | disclosed |
| US-4855307-A | Acetic acid ester of haloperidol | H. LUNDBECK A/S (DK) | 1989-08-08 | — | — | US | disclosed |
| EP-0260070-A1 | The acetic acid ester of haloperidol and pharmaceutical compositions thereof | H. LUNDBECK A/S (DK) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183001-B1 | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features | OPRM1, OPRD1, OPRL1 | DRD2 9/4885HTR2A 61/4885DRD3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.